CN108968025A - Adjust the high concentration lactic acid bacteria freeze drying powder of blood pressure and blood lipoid - Google Patents
Adjust the high concentration lactic acid bacteria freeze drying powder of blood pressure and blood lipoid Download PDFInfo
- Publication number
- CN108968025A CN108968025A CN201810605155.6A CN201810605155A CN108968025A CN 108968025 A CN108968025 A CN 108968025A CN 201810605155 A CN201810605155 A CN 201810605155A CN 108968025 A CN108968025 A CN 108968025A
- Authority
- CN
- China
- Prior art keywords
- lactic acid
- acid bacteria
- powder
- freeze
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 239000000843 powder Substances 0.000 title claims abstract description 69
- 241000894006 Bacteria Species 0.000 title claims abstract description 50
- 238000004108 freeze drying Methods 0.000 title claims abstract description 44
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 42
- 239000004310 lactic acid Substances 0.000 title claims abstract description 42
- 210000004369 blood Anatomy 0.000 title claims abstract description 28
- 239000008280 blood Substances 0.000 title claims abstract description 28
- 230000036772 blood pressure Effects 0.000 title claims abstract description 16
- 239000006041 probiotic Substances 0.000 claims abstract description 18
- 235000018291 probiotics Nutrition 0.000 claims abstract description 18
- 150000004676 glycans Chemical class 0.000 claims abstract description 17
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 16
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 16
- 239000005017 polysaccharide Substances 0.000 claims abstract description 16
- 230000002779 inactivation Effects 0.000 claims abstract description 13
- 239000006166 lysate Substances 0.000 claims abstract description 12
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 10
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 10
- 241001506047 Tremella Species 0.000 claims abstract description 8
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 238000005119 centrifugation Methods 0.000 claims description 11
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 10
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 8
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 7
- 241000186012 Bifidobacterium breve Species 0.000 claims description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- 244000199866 Lactobacillus casei Species 0.000 claims description 6
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 6
- 239000005862 Whey Substances 0.000 claims description 6
- 102000007544 Whey Proteins Human genes 0.000 claims description 6
- 108010046377 Whey Proteins Proteins 0.000 claims description 6
- 235000013351 cheese Nutrition 0.000 claims description 6
- 229940017800 lactobacillus casei Drugs 0.000 claims description 6
- 229920002444 Exopolysaccharide Polymers 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 241001608472 Bifidobacterium longum Species 0.000 claims description 4
- 240000001929 Lactobacillus brevis Species 0.000 claims description 4
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 4
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 102000014171 Milk Proteins Human genes 0.000 claims description 3
- 108010011756 Milk Proteins Proteins 0.000 claims description 3
- 241000218231 Moraceae Species 0.000 claims description 3
- 235000008708 Morus alba Nutrition 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 108010084695 Pea Proteins Proteins 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 3
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- 235000021014 blueberries Nutrition 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 235000021239 milk protein Nutrition 0.000 claims description 3
- 235000019702 pea protein Nutrition 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 235000019710 soybean protein Nutrition 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 235000013948 strawberry juice Nutrition 0.000 claims description 3
- 235000015193 tomato juice Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 235000013406 prebiotics Nutrition 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 abstract description 10
- 230000036039 immunity Effects 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 8
- 230000001976 improved effect Effects 0.000 abstract description 4
- 230000000968 intestinal effect Effects 0.000 abstract description 4
- 230000008944 intestinal immunity Effects 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 9
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 240000004371 Panax ginseng Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- LIEMBEWXEZJEEZ-INEUFUBQSA-N (2r,3r)-4-(6-aminopurin-9-yl)-2,3-dihydroxybutanoic acid Chemical compound NC1=NC=NC2=C1N=CN2C[C@@H](O)[C@@H](O)C(O)=O LIEMBEWXEZJEEZ-INEUFUBQSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- LIEMBEWXEZJEEZ-UHFFFAOYSA-N D-threo-Leutysin Natural products NC1=NC=NC2=C1N=CN2CC(O)C(O)C(O)=O LIEMBEWXEZJEEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000577951 Hydnum Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- PUGBZUWUTZUUCP-ZRKHGVCBSA-N fungisterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@H](C)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 PUGBZUWUTZUUCP-ZRKHGVCBSA-N 0.000 description 1
- UHQOYWRQNBWEAM-NBPRQAIYSA-N fungisterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@@H]1CC[C@@H]2C3=C(CC[C@]12C)[C@@]4(C)CC[C@@H](O)C[C@H]4C=C3 UHQOYWRQNBWEAM-NBPRQAIYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/121—Brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of high concentration lactic acid bacteria freeze drying powder and preparation method thereof for adjusting blood pressure and blood lipoid, its main component includes: inactivation 1-100 parts of lactic acid bacteria freeze drying powder, 1-100 parts of probiotics extracellular polysaccharide extractive freeze-dried powder, 1-10 parts of probiotics lysate extract freeze-drying powder, 0-10 parts of ginseng extract, 0-10 parts of Shitake Mushroom P.E, 0-10 parts of Hericium erinaceus extract, 0-10 parts of dried tremella extract, wherein ginseng extract, Shitake Mushroom P.E, Hericium erinaceus extract, dried tremella extract content not simultaneously be 0.Intestinal flora is adjusted, intestinal immunity is improved, alleviates chemical damage, the main essence and blood of liver improves immunity of organisms, to have the function that adjust blood pressure and blood lipid.
Description
Technical field
It is specifically a kind of through excessively high the present invention relates to a kind of high concentration lactic acid bacteria freeze drying compound powder for adjusting blood pressure and blood lipoid
The lactic acid bacteria freeze drying powder for spending concentration adjusts blood pressure and blood lipoid by improving immunity etc..
Background technique
Hypertension, the basic pathogenesis of hyperlipidemia are after enteric microorganism is lacked of proper care, and intestinal permeability change causes endogenous toxic material
Plain horizontal raising, causes organ metabolism that disadvantageous changes occur.Most typical conditioned pathogen includes intestines bar after intestinal bacilli illness
Enterobacter cloacae, pseudomonas aeruginosa and sulfate reducing bacteria of Cordycepps etc..When enteric microorganism is unbalance, conditioned pathogen increases
It is more, immunity of organism will be further influenced, vicious circle is generated.Enteropathic is mostly gramnegative bacterium, this kind of micro- life
The LPS (lipopolysaccharides) that object carries is main endotoxin ingredient, and endotoxin increases induction collective and generates chronic inflammation, changes enteron aisle
Permeability, and further induce hypertension, hyperlipidemia, obesity, a series of chronic diseases such as diabetes.
It is combined by taking high concentration probiotics and its extracellular polysaccharide extractive, can quickly adjust intestinal immunity, it is fast
Speed inhibits the proliferation of harmful intestinal tract bacteria, while beneficial bacterium being promoted to grow, and adjusts intestinal microecology balance to reach, controls chronic
Inflammation alleviates endotoxin and enters a series of inflammation caused by blood, can reduce the level of blood glucose and blood lipid faster.
But there are no a kind of probiotics that superelevation is dense inactivation thallus and its extracellular polysaccharide extractive occur currently on the market
Combination product, come dedicated for treating or preventing or improve hyperglycemia, blood lipid.
Summary of the invention
The technical problem to be solved by the present invention is to for the above-mentioned prior art provide it is a kind of adjust blood pressure and blood lipoid it is highly concentrated
Lactic acid bacteria freeze drying powder is spent, it is convenient to take, diabetic can be helped to adjust blood pressure and blood lipoid by adjusting immunity after taking.
The present invention solves the above problems used technical solution are as follows: a kind of high concentration lactic acid bacteria for adjusting blood pressure and blood lipoid is frozen
Dry powder, it is characterised in that: its main component includes: 1-100 parts of lactic acid bacteria freeze drying powder of inactivation, probiotics extracellular polysaccharide extractive jelly
1-100 parts of dry powder, 1-10 parts of probiotics lysate extract freeze-drying powder, 0-10 parts of ginseng extract, 0-10 parts of Shitake Mushroom P.E,
0-10 parts of Hericium erinaceus extract, 0-10 parts of dried tremella extract, wherein ginseng extract, Shitake Mushroom P.E, Hericium erinaceus extract, silver
The content of ear extract is not 0 simultaneously.
In the application, inactivation lactic acid bacteria freeze drying powder be selected from lactobacillus plantarum, cheese sugar lactobacillus, lactobacillus paracasei,
One of Lactobacillus brevis, bifidobacterium lactis, bifidobacterium breve are a variety of through ultra high density fermented and cultured, centrifugation and vacuum drying
The Freeze-dry Powder of Probioctics composition of the high activity of acquisition.
Further, inactivation lactic acid bacteria freeze drying powder is will to be selected from lactobacillus plantarum, cheese sugar lactobacillus, secondary cheese cream bar
One of bacterium, Lactobacillus brevis, bifidobacterium lactis, bifidobacterium breve or a variety of 24-48h feed supplements of fermenting at a temperature of 25-45 DEG C
Culture, OD value grow to 30, then the vacuum drying treatment after being centrifuged, and dry latter stage is kept for 85 DEG C of temperature, duration 6-
12h, inactivation lactobacillus cell concentration reaches 10 in the high concentration lactic acid bacteria freeze drying powder13CFU/g。
In the application, the preparation method of probiotics extracellular polysaccharide extractive freeze-dried powder is with Lactobacillus casei, long bifid bar
Bacterium, bifidobacterium breve, Lactobacillus helveticus and streptococcus thermophilus are in whey medium through 25-40 DEG C of fermentation 48-96h, culture medium
Exocellular polysaccharide is generated, freeze-drying obtains exocellular polysaccharide freeze-drying compound powder after alcohol precipitation, centrifugation；The matter of the culture medium
Measure percentage proportion: mannose 1-10%, xylose 1-10%, melezitose 1-10%, gossypose 1-10%, xylitol 1-10%,
Lactitol 1-10%, antierythrite 1-10%, PURE WHEY 1-10%, soybean protein isolate 1-10%, Evamilk albumen
1-10%, milk protein isolate 1-10%, whole-fat milk powder 1-10%, skimmed milk powder 1-10%, pea protein 1-10%, rice egg
White 1-10%, blueberry juice 1-10%, Tomato juice 1-10%, strawberry juice 1-10%, brewer's wort 1-10%, in mulberries powder 1-10%
One or more, the content of Exopolysaccharides Produced by Lactic Acid Bacteria reaches 50% (wt) in the high concentration lactic acid bacteria freeze drying powder.
In the application, the preparation method of probiotics lysate extract freeze-drying powder be with bifidobacterium lactis, lactobacillus plantarum,
One or more of lactobacillus acidophilus, bifidobacterium adolescentis, lactobacillus paracasei, through 25-45 DEG C of fermented and cultured 48-96h,
It is broken with high-shear emulsifying head after centrifugation is resuspended, lactic acid thallus fermented, that moist heat sterilization obtains after centrifugation is added, through cold
Dry rear acquisition is lyophilized, the content of lactic acid bacteria lysate freeze-dried powder reaches 10% (wt) in the high concentration lactic acid bacteria freeze drying powder.
Lactobacillus plantarum (Lactobacillus plantarum), Lactobacillus casei (Lactobacillus casei),
Lactobacillus rhamnosus (Lactobacillus rhamnosus), bifidobacterium longum (Bifidobacerium longum) are a kind of
It is usually used in the probiotics of Yoghourt, fermented dairy product and dietary supplements, be put into Ministry of Public Health's announcement " can be used for the strain of food
List " (defend and do supervision hair [2010] 65), the colony balance of enteron aisle can be kept.Bifidobacterium longum and Lactobacillus casei are fermenting
It can produce exocellular polysaccharide in the process, as a kind of macromolecule polyalcohol, exocellular polysaccharide has certain viscosity and retentiveness, extracellular
Polysaccharide is also a kind of effective immune factor, after specific culture medium culture, can reinforced immunological effect, culture medium be selected from class
Sugar, sugar alcohol and fruit and vegetable juice and milk albuminoid, do not add animal protein, do not contain tallow, thus it is more healthy, even
Diabetic can also trust and take, and hardly generate side effect.
Compatibility profitable probliotics lysate extract freeze-drying powder, foundation are because probiotics used contains to the application in the product
Biological enzyme intracellular, peptide glycan, teichoic acid and the proteoglycan isoreactivity substance of high concentration, because these substances are with very strong
The effect for improving immunity, can be enhanced effect of the Freeze-dry Powder of Probioctics in terms of enteric microorganism adjusting.It can by high shear
There is immunocompetent substance sufficiently to discharge lactic acid bacteria, immunity stimulation is significantly increased.
In addition the application is added to various food, medicinal substances extract, be beneficial in that
Ginseng extract: ginseng has " tonifying five zang organs soothe the nerves, determine soul, stop palpitate with fear, remove pathogenic factor, the happy intelligence development of improving eyesight "
Effect, " long term usage make light of one's life by commiting suicide macrobiosis ".Ginseng is not really false to the effect for keeping fit and healthy, prolonging life.Through modern medicine study and change
Test analysis shows, a kind of chemical substance for being panaxoside is contained in ginseng, it to adjust the central nervous system of people, heart tonifying,
Antifatigue, Auto-regulator metabolism etc. has obvious effect, so to treatment nervous system cardiovascular system, endocrine system and life
The a variety of diseases for growing system have good therapeutic effect, for the application primarily to adjusting the immunity of matrix.
Shitake Mushroom P.E: mushroom contains lentinan, contain reduce blood lipid ingredient: Eritadenine, mushroom adenine and
The derivative of adenine, mushroom also contain antiviral ingredient: inducing agent, the double stranded RNA of interferon, are rare
One of health food.It is very high containing unsaturated fatty acid in mushroom, also containing the ergosterol that can be largely changed into vitamin D
And fungisterol, there is good result for enhancing anti-disease and preventing cold and treatment.In addition, containing one kind " β-grape in mushroom
Glycosidase ", test prove that this substance plays the role of significantly reinforcing body against cancer, and therefore, mushroom is called " anticancer by people
New recruit ".Mushroom is also resistant to common cold virus, because containing a kind of inducer of interferon in mushroom, can induce the production of internal interferon
Raw, the synthesis of viral interference protein keeps its irreproducible, so that human body be made to generate immunization.
Hericium erinaceus extract: Hericium erinaceus improves a poor appetite, and enhances barrier of gastric mucosa function, improves lymphocyte transformation rate,
The effects of promoting leucocyte.Therefore human body can be made to improve the immunocompetence to disease.Hedgehog hydnum or good nourishing food, to mind
There is good efficacy through weak, digestive tract ulcer.The application selects Hericium erinaceus extract that can help user's coordinating intestines and stomach, improves
Stomach function.
Dried tremella extract: there is tonifying spleen appetizing, QI invigorating gut purge, sleeping stomach invigorating, cerebrum tonifying, nourishing yin and clearing heat, the function moisturized, to yin
The prosperous fire of deficiency type not is a kind of good tonic by the patient that ginseng and pilose antler Isothermal Hot nourishes, and is especially suitable for hyperglycemia blood lipid patient.Tremella is
Diet food of the kind containing dietary fiber, its dietary fiber can help gastrointestinal peristalsis, reduce fat absorption.In addition, it can be improved
Liver detoxification ability protects liver function, it can not only enhance the antitumor immunocompetence of body, moreover it is possible to enhance tumor patient pair
Radiotherapy, chemotherapy tolerance.It can nourish and promote the production of body fluid；Moistening lung nourishing the stomach, invigorating the lung and benefiting vital QI.Saliva is few thirsty；It is physically weak after being ill；Shortness of breath and fatigue.
Compared with the prior art, the advantages of the present invention are as follows: the present invention provides a kind of specific ratios of specific function probiotics
The combination of example can change the composition of enteric microorganism by taking the combination, adjust intestinal flora, improve intestinal immunity,
Alleviate chemical damage, the main essence and blood of liver improves immunity of organisms, to have the function that adjust blood pressure and blood lipid.
Specific embodiment
Present invention is further described in detail with reference to embodiments.
This application involves the lactic acid bacteria freeze drying powder productions that a kind of help hypertensive patient, diabetic adjust blood lipid, blood glucose
Product, 15 parts of lactic acid bacteria freeze drying powder of inactivation, 50 parts of probiotics extracellular polysaccharide extractive freeze-dried powder, the freeze-drying of probiotics lysate extract
10 parts of powder, 5 parts of ginseng extract, 5 parts of Shitake Mushroom P.E, 5 parts of Hericium erinaceus extract, 10 parts of dried tremella extract are mixed above-mentioned raw materials
Close the composition for uniformly obtaining Freeze-dry Powder of Probioctics.The content of Exopolysaccharides Produced by Lactic Acid Bacteria reaches in the high concentration lactic acid bacteria freeze drying powder
Reach 10 to 50% (wt), inactivation lactobacillus cell concentration13CFU/g, lactic acid bacteria lysate freeze-dried powder content reach 10%
(wt)。
Above-mentioned inactivation lactic acid bacteria freeze drying powder is will to be selected from lactobacillus plantarum, cheese sugar lactobacillus, lactobacillus paracasei, short cream
One of bacillus, bifidobacterium lactis, bifidobacterium breve or a variety of 24-48h feed-batch cultures that ferment at a temperature of 25-45 DEG C, allow
OD value grows to 30, then vacuum drying treatment is carried out after being centrifuged, and dry latter stage is kept for 85 DEG C of temperature, duration 6-12h.
The preparation method of above-mentioned probiotics extracellular polysaccharide extractive freeze-dried powder is with Lactobacillus casei, bifidobacterium longum, short
Through 25-40 DEG C of fermentation 48-96h in whey medium, culture medium generates born of the same parents for Bifidobacterium, Lactobacillus helveticus and streptococcus thermophilus
Exo polysaccharides obtain exocellular polysaccharide freeze-drying compound powder with freeze-drying after alcohol precipitation, centrifugation.The quality percentage of prior culture media
Than proportion: mannose 1-10%, xylose 1-10%, melezitose 1-10%, gossypose 1-10%, xylitol 1-10%, lactitol
1-10%, antierythrite 1-10%, PURE WHEY 1-10%, soybean protein isolate 1-10%, Evamilk albumen 1-10%,
Milk protein isolate 1-10%, whole-fat milk powder 1-10%, skimmed milk powder 1-10%, pea protein 1-10%, rice protein 1-
10%, blueberry juice 1-10%, Tomato juice 1-10%, strawberry juice 1-10%, brewer's wort 1-10%, mulberries powder 1-10%.
The preparation method of above-mentioned probiotics lysate extract freeze-drying powder is with bifidobacterium lactis, lactobacillus plantarum, acidophilus
One or more of lactobacillus, bifidobacterium adolescentis, lactobacillus paracasei, through 25-45 DEG C of fermented and cultured 48-96h, through from
It is broken with high-shear emulsifying head after the heart is resuspended, lactic acid thallus fermented, that moist heat sterilization obtains after centrifugation is added, it is chilled dry
It is obtained after dry, the content of lactic acid bacteria lysate freeze-dried powder reaches 10% (wt) in the high concentration lactic acid bacteria freeze drying powder.
The instructions of taking of high concentration lactic acid bacteria freeze drying powder, it is bfore meals each taking 5-30 grams, it continuously takes 28 days, it can
Lower blood pressure and blood lipids index, after taking for a long time according to particular requirement and dosage, can achieve raising immunity, reduce endotoxic
Effect.
It is illustrated below by way of effect of the clinical test to the application product
One, beneficial effect of this product to hypertensive patient
Choose 50 people of hypertensive patient, all cholesterol and triglycerides preference crowd, Diagnostic Value of Fasting Serum total cholesterol
(TC) > 6.5mml/L, triglycerides (TG) > 1.24mml/L.Compound Evaluation of Diagnostic Criteria of Hypertension: diastolic pressure >=90mmHg.It is clinical
Show as headache, dizziness.Age 40-55 years old, average age 50.2 years old, wherein male 30, women 20.Control group and experiment
Group men and women patient is fifty-fifty, and two groups of average ages are suitable.
Instructions of taking: experimental group is continuously taken above-mentioned high concentration and is inactivated freeze-dried powder 28 days, and daily 30 grams, control group takes egg
White powder.
Observation index: effective: clinical symptoms disappear, diastole drops >=10mmHg, and TC declines > 20%, and TG declines >
40%；Effective: clinical symptoms are obviously improved, diastole drops >=10mmHg, and TC decline > 10~20%, TG decline > 20~
40%；Invalid: clinical symptoms are not improved, and TC declines < 10%, and TG is dropped by less than 20%.
Test result:
(1) Comparison of therapeutic: referring to table 1, the total effective rate of experimental group and control group is respectively 98.6% and 88.4%, experiment
Group always has
Efficiency is apparently higher than control group (p < 0.05).The obvious effective rate of experimental group be equally apparently higher than control group (p <
0.05)。
The Comparison of therapeutic of table 1 experimental group and control group
| Group | Number of cases | Significantly | Effectively | In vain | Total effective rate |
| Control group | 25 | 10 | 12 | 3 | 88% |
| Experimental group | 25 | 2 | 6 | 17 | 32% |
(2) blood lipids index compares: referring to table 2, the comparison of TG and TC value is poor without statistics before experimental group and control group test
Different (p > 0.05), TG and TC value is substantially reduced (p < 0.05) after test, and comparison has statistical difference (p between group in group
< 0.05).Experimental group diastolic pressure drop-out value is significantly greater than control group simultaneously.
2 experimental group of table and the blood lipids index of control group change table
Two, beneficial effect of this product to diabetic
Selection state of an illness after diet control or oral hypoglycemic agents treatment is more stable, does not need replacement types of drugs and dosage,
Adult Patients with NIDDM 100 for only taking maintenance dose, participate in test patient selection criteria: fasting blood-glucose >=
7.8mmol/L (140mg/dL) or 2h-plasma glucose >=11.1mmol/L (200mg/dL).During test, experimenter deactivates treatment
Diabetes medicament and other in relation to health food, take inactivated bacteria powder provided by the invention, 3 times a day, each 30g is before meals
With continuously taking 2 months.
Test the result shows that, after patients with NIDDM takes composition of the invention, polydipsia, polyorexia,
The main clinic symptoms such as fatigue and weakness, diuresis have clear improvement, and no side effects during taking.
Experiments have shown that this product can improve malaise symptoms to diabetic.
In addition to the implementation, all to use equivalent transformation or equivalent replacement the invention also includes there is an other embodiments
The technical solution that mode is formed should all be fallen within the scope of the hereto appended claims.
Claims (5)
1. a kind of high concentration lactic acid bacteria freeze drying powder for adjusting blood pressure and blood lipoid, it is characterised in that: its main component includes: inactivation lactic acid
1-100 parts of bacterium freeze-dried powder, 1-100 parts of probiotics extracellular polysaccharide extractive freeze-dried powder, probiotics lysate extract freeze-drying powder 1-
10 parts, 0-10 parts of ginseng extract, 0-10 parts of Shitake Mushroom P.E, 0-10 parts of Hericium erinaceus extract, 0-10 parts of dried tremella extract,
Middle ginseng extract, Shitake Mushroom P.E, Hericium erinaceus extract, dried tremella extract content not simultaneously be 0.
2. the high concentration lactic acid bacteria freeze drying powder according to claim 1 for adjusting blood pressure and blood lipoid, it is characterised in that: the inactivation
Lactic acid bacteria freeze drying powder is selected from lactobacillus plantarum, cheese sugar lactobacillus, lactobacillus paracasei, Lactobacillus brevis, bifidobacterium lactis, short
One of Bifidobacterium or the probiotics of a variety of high activities obtained through ultra high density fermented and cultured, centrifugation and vacuum drying are frozen
Dry powder composite.
3. the high concentration lactic acid bacteria freeze drying powder according to claim 2 for adjusting blood pressure and blood lipoid, it is characterised in that: the inactivation
Lactic acid bacteria freeze drying powder be will selected from lactobacillus plantarum, cheese sugar lactobacillus, lactobacillus paracasei, Lactobacillus brevis, bifidobacterium lactis,
One of bifidobacterium breve or a variety of 24-48h feed-batch cultures that ferment at a temperature of 25-45 DEG C, OD value grows to 30, then passes through
Vacuum drying treatment after centrifugation, dry latter stage are kept for 85 DEG C of temperature, duration 6-12h, in the high concentration lactic acid bacteria freeze drying powder
Inactivation lactobacillus cell concentration reaches 1013CFU/g。
4. the high concentration lactic acid bacteria freeze drying powder according to claim 1 for adjusting blood pressure and blood lipoid, it is characterised in that: described prebiotic
The preparation method of bacterium exopolysaccharide extract freeze-drying powder is with Lactobacillus casei, bifidobacterium longum, bifidobacterium breve, Switzerland's cream bar
Through 25-40 DEG C of fermentation 48-96h in whey medium, culture medium generates exocellular polysaccharide, heavy through alcohol for bacterium and streptococcus thermophilus
It forms sediment, freeze-drying obtains exocellular polysaccharide freeze-drying compound powder after centrifugation；The mass percent of the culture medium matches: mannose 1-
10%, xylose 1-10%, melezitose 1-10%, gossypose 1-10%, xylitol 1-10%, lactitol 1-10%, antierythrite
1-10%, PURE WHEY 1-10%, soybean protein isolate 1-10%, Evamilk albumen 1-10%, milk protein isolate 1-
10%, whole-fat milk powder 1-10%, skimmed milk powder 1-10%, pea protein 1-10%, rice protein 1-10%, blueberry juice 1-
10%, one or more of Tomato juice 1-10%, strawberry juice 1-10%, brewer's wort 1-10%, mulberries powder 1-10%, should
The content of Exopolysaccharides Produced by Lactic Acid Bacteria reaches 50% (wt) in high concentration lactic acid bacteria freeze drying powder.
5. the high concentration lactic acid bacteria freeze drying powder according to claim 1 for adjusting blood pressure and blood lipoid, it is characterised in that: described prebiotic
The preparation method of bacterium lysate extract freeze-drying powder is with bifidobacterium lactis, lactobacillus plantarum, lactobacillus acidophilus, youth bifid bar
One or more of bacterium, lactobacillus paracasei use high shear after centrifugation is resuspended through 25-45 DEG C of fermented and cultured 48-96h
Emulsifying head is broken, and lactic acid thallus fermented, that moist heat sterilization obtains after centrifugation is added, obtains after freeze-dried, the high concentration
The content of lactic acid bacteria lysate freeze-dried powder reaches 10% (wt) in lactic acid bacteria freeze drying powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810605155.6A CN108968025A (en) | 2018-06-13 | 2018-06-13 | Adjust the high concentration lactic acid bacteria freeze drying powder of blood pressure and blood lipoid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810605155.6A CN108968025A (en) | 2018-06-13 | 2018-06-13 | Adjust the high concentration lactic acid bacteria freeze drying powder of blood pressure and blood lipoid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108968025A true CN108968025A (en) | 2018-12-11 |
Family
ID=64541232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810605155.6A Pending CN108968025A (en) | 2018-06-13 | 2018-06-13 | Adjust the high concentration lactic acid bacteria freeze drying powder of blood pressure and blood lipoid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108968025A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109674671A (en) * | 2019-01-07 | 2019-04-26 | 广州市拓瑞科技有限公司 | The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid |
| CN113287751A (en) * | 2021-05-07 | 2021-08-24 | 济南万泉生物技术有限公司 | Composite probiotics and preparation method and application thereof |
| CN113662188A (en) * | 2021-09-17 | 2021-11-19 | 吉林省昆蓉科技有限公司 | Functional food suitable for diabetes patients and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125151A (en) * | 2006-08-16 | 2008-02-20 | 大连森佰澳科技有限公司 | Bacteroides signal molecule microecological preparation and its preparation method |
| CN101953855A (en) * | 2009-07-21 | 2011-01-26 | 明博医药技术开发（上海）有限公司 | Preparation method and application for lactobacillus cell wall lysate |
| CN105274044A (en) * | 2015-11-05 | 2016-01-27 | 胡文锋 | Inactivated lactic acid bacterium cell and application thereof to food |
| CN107158231A (en) * | 2017-06-07 | 2017-09-15 | 马凯 | A kind of composition for the probiotics fermention Chinese herbal medicine for preventing and controlling diabetes |
| CN107308190A (en) * | 2017-07-04 | 2017-11-03 | 宇萃达生物科技（苏州）有限公司 | Adjust the probiotic composition and its culture, preparation, purposes of human body microecological balance |
| FR3040624B1 (en) * | 2015-09-09 | 2019-07-26 | Gallinee Ltd | COMPOSITIONS COMPRISING IN ASSOCIATION PREBIOTICS, PROBIOTIC FRACTIONS AND LACTIC ACID |
-
2018
- 2018-06-13 CN CN201810605155.6A patent/CN108968025A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101125151A (en) * | 2006-08-16 | 2008-02-20 | 大连森佰澳科技有限公司 | Bacteroides signal molecule microecological preparation and its preparation method |
| CN101953855A (en) * | 2009-07-21 | 2011-01-26 | 明博医药技术开发（上海）有限公司 | Preparation method and application for lactobacillus cell wall lysate |
| FR3040624B1 (en) * | 2015-09-09 | 2019-07-26 | Gallinee Ltd | COMPOSITIONS COMPRISING IN ASSOCIATION PREBIOTICS, PROBIOTIC FRACTIONS AND LACTIC ACID |
| CN105274044A (en) * | 2015-11-05 | 2016-01-27 | 胡文锋 | Inactivated lactic acid bacterium cell and application thereof to food |
| CN107158231A (en) * | 2017-06-07 | 2017-09-15 | 马凯 | A kind of composition for the probiotics fermention Chinese herbal medicine for preventing and controlling diabetes |
| CN107308190A (en) * | 2017-07-04 | 2017-11-03 | 宇萃达生物科技（苏州）有限公司 | Adjust the probiotic composition and its culture, preparation, purposes of human body microecological balance |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109674671A (en) * | 2019-01-07 | 2019-04-26 | 广州市拓瑞科技有限公司 | The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid |
| CN113287751A (en) * | 2021-05-07 | 2021-08-24 | 济南万泉生物技术有限公司 | Composite probiotics and preparation method and application thereof |
| CN113662188A (en) * | 2021-09-17 | 2021-11-19 | 吉林省昆蓉科技有限公司 | Functional food suitable for diabetes patients and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sen | Role of probiotics in health and disease–A review | |
| EP1478246B1 (en) | Dietetic and/or pharmaceutical compositions for human and/or animal use based on probiotic microbial preparations | |
| CN109123295A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| CN108991327A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| JP5000066B2 (en) | Conversion and modification of natural drugs by co-fermentative culture of intestinal symbiotic organisms | |
| CN103131647B (en) | Bifidobacterium infantis and its preparation | |
| CN105146614A (en) | Functional Chinese dwarf cherry seed ferment, ferment beverage and production method of ferment beverage | |
| CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
| JPH0656680A (en) | Nutritional and/or pharmaceutical composi- tion containing freeze-dried lactic acid bacterium and preparation and use thereof | |
| CN109481510A (en) | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof | |
| CN107158231A (en) | A kind of composition for the probiotics fermention Chinese herbal medicine for preventing and controlling diabetes | |
| WO2001085186A1 (en) | Preparation that contains the intestinal beneficial bacterium fermentation culture | |
| CN108850397A (en) | A kind of probiotic gel candy and preparation method thereof of only diarrhea | |
| CN115074298A (en) | Probiotic composition with effects of resisting claustrophobia, protecting stomach and promoting digestion and eliminating stagnation and application thereof | |
| CN108968025A (en) | Adjust the high concentration lactic acid bacteria freeze drying powder of blood pressure and blood lipoid | |
| EP3806867A1 (en) | Collagen and cell matter supplement and method for administering same | |
| CN108785331A (en) | It is a kind of that there is qi-blood tonifying composition and its preparation method and application | |
| US6368641B1 (en) | Lactic acid bacteria and food products | |
| CN108795823B (en) | It is a kind of improve women pregnant and lying-in women's intestinal flora probiotics cultural method and application | |
| JP2013538827A (en) | Compositions and methods for enhancing renal function | |
| TW202207957A (en) | Novel bifidobacterium breve idcc 4401 strain having high resistance ability of acid and bile salt and effect of preventing or treating dyslipidemia, and their killed form id-bbr4401 | |
| CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
| CN111296847A (en) | Cereal probiotic preparation for regulating intestinal microecology and preparation method and application thereof | |
| JP4688457B2 (en) | Immune enhancing composition | |
| CN102742654B (en) | Beautification probiotic ewe milk tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181211 |
|
| RJ01 | Rejection of invention patent application after publication |